Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dysbiosis of the Gut Microbiota

Dysbiosis of the Gut Microbiota

The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quality of Evidence Backing Recommendations for Eosinophilic Esophagitis.

The American journal of gastroenterology·2025

Same author

Optimizing Screening Strategies for Hypertension in India: A Consensus Statement.

The Journal of the Association of Physicians of India·2025

Same author

Early Readmissions after Esophagectomy for Esophageal Adenocarcinoma: Does Facility Case-Volume Matter?

Surgery research and practice·2020

Same author

Readmissions related to short bowel syndrome: a study from a national database.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2019

Same author

Risk factors for Clostridium difficile infection in pediatric inpatients: A meta-analysis and systematic review.

Infection control and hospital epidemiology·2019

Same author

Hospital readmissions related to Clostridium difficile infection in the United States.

American journal of infection control·2017

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Does PPI therapy predispose to Clostridium difficile infection?

Chaitanya Pant¹, Phillip Madonia, Anil Minocha

¹Louisiana State University Health Sciences Center and Overton Brooks VA Medical Center, Shreveport, LA, USA.

Nature Reviews. Gastroenterology & Hepatology

|August 29, 2009

Summary

Proton pump inhibitors (PPIs) are increasingly linked to Clostridium difficile infection (CDI), a significant healthcare concern. Research suggests a modest association between PPI therapy and the development of this infection, even with observational data.

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Area of Science:

Gastroenterology
Infectious Diseases
Pharmacology

Background:

Clostridium difficile infection (CDI) is a major healthcare-associated problem.
Broad-spectrum antibiotic use is a primary risk factor for CDI.
Proton pump inhibitors (PPIs) are frequently overprescribed, prompting investigation into their role in CDI.

Purpose of the Study:

To investigate the association between proton pump inhibitor (PPI) therapy and the risk of developing Clostridium difficile infection (CDI).

Main Methods:

Review of observational studies examining PPI use and CDI incidence.
Analysis of existing epidemiological data on PPI prescription patterns and CDI rates.

Main Results:

Increasing evidence suggests a link between PPI use and CDI.
The association appears to be modest but significant, based on current observational data.

Conclusions:

Proton pump inhibitor therapy may contribute to the risk of Clostridium difficile infection.
Further research is warranted to elucidate the precise mechanisms and clinical implications of this association.